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Abstract
Background: Although a dramatic decrease in AIDS progression has been observed after Highly Active Anti Retroviral 
Therapy (HAART) in both low- and high-resource settings, few data support that fact in low-resource settings.
This study describes the incidence of AIDS-defining illnesses (ADI) after HAART initiation and analyzes their risk factors 
in a low-resource setting. A focus was put on CD4 cell counts and viral load measurements.
Methods: 404 HIV-1-infected Senegalese adult patients were enrolled in a prospective observational cohort and data 
censored as of April 2008. A Poisson regression was used to model the incidence of ADIs over two periods and to assess 
its association with baseline variables, current CD4, current viral load, CD4 response, and virological response.
Results: ADI incidence declined from 20.5 ADIs per 100 person-years, 95% CI = [16.3;25.8] during the first year to 4.3, 
95% CI = [2.3;8.1] during the fourth year but increased afterwards. Before 42 months, the decrease was greater in 
patients with clinical stage CDC-C at baseline and with a viral load remaining below 1000 cp/mL but was uniform 
across CD4 strata (p = 0.1). After 42 months, 293 patients were still at risk. The current CD4 and viral load were 
associated with ADI incidence (decrease of 21% per 50 CD4/mm3 and of 61% for patients with a viral load < 1000 cp/
mL).
Conclusions: During the first four years, a uniform decline of ADI incidence was observed even in patients with low 
CD4-cell counts at HAART initiation as long as the viral load remained undetectable. An increase was noted later in 
patients with immunologic and virological failures but also in patients with only virological failure.
Background
Since the advent of Highly Active Anti Retroviral Therapy
(HAART), a dramatic decrease in AIDS progression has
been observed in both developed [1-5] and developing
countries [6,7]. However, some differences still exist. For
instance, the nature of the most frequent AIDS-defining
illnesses (ADI) differs between low-resource and indus-
trialized countries [8]; tuberculosis and recurrent bacte-
rial infections are most often observed in the former
setting than in the latter [6,7,9,10]. Therefore, results
from high-income countries cannot be unreservedly used
in low-income ones.
Observational studies have identified the CD4 cell
count and the history of AIDS as the strongest predictors
of disease progression [5,7,11-18]. The viral load and the
virological response (change in the viral load) were also
found associated with disease progression [10,19], but
this association was less often studied and sometimes
found to be weak [20]. Whereas the CD4 cell count is
undoubtedly a key marker in monitoring the response to
treatment in low-resource settings [21], the place of viral
load testing is still under debate [22-24] especially
because it is expensive and its feasibility and benefits in
such settings are not yet demonstrated. Therefore, the
evaluation of the relationships between these longitudinal
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markers and the occurrence of ADI is important to deter-
mine the markers' practical utility.
To date, there are few studies about disease progression
in low-resource settings and most have short follow-up
durations. Nevertheless, as the access to antiretroviral
therapy in such settings is scaled up, there is a need for
further knowledge on long-term outcomes in patients put
on HAART and for evaluation of clinical or biological
markers for patient monitoring. The present study
describes the incidence and nature of the most common
ADI in a low resource setting and examines the relation-
ships between clinical and biological markers and the
occurrence of ADI.
Methods
Study design
From August 1998 to April 2002, 404 HIV-1 infected
patients aged 15 or more and participating in the "Initia-
tive Sénégalaise d'Accès aux médicaments Antirétrovir-
aux" (ISAARV) were enrolled in an observational cohort
after giving written informed consent. The data were cen-
sored either at the last visit before April 2008 or at the
date of death.
The initial antiretroviral therapy regimen was a triple
drug combination (two nucleoside reverse transcriptase
inhibitors (NRTI) + either one non-nucleoside reverse
transcriptase inhibitor (NNRTI) or one protease inhibitor
(PI)), except for 18 patients who received only two NRTI
until May 2000. Antiretroviral drugs were provided for
free starting from December 2003.
After comprehensive clinical and biological assess-
ments at inclusion, patients were examined at least every
2 months and had a biological evaluation at least every 6
months. A patient record and a Case Report Form that
includes a comprehensive list of various ADIs were made
available to the investigator at each patient visit.
Patients' monitoring details, characteristics at baseline,
antiretroviral treatment efficacy, adherence to treatment,
and mortality pattern (early or late) have been previously
published [25-28]. The study was approved by the Sene-
galese National Committee for Health Research (CNRS).
Outcomes
The primary outcome for the present analysis was the
occurrence of a new CDC stage C event (ADI) as defined
by the CDC revised classification of 1993 [8]. Only ADIs
occurring after HAART initiation were considered.
Because it is sometimes difficult to tell whether an event
is a relapse or a first episode, only the first event of each
ADI was considered in the analysis.
Laboratory tests
CD4 cell counts were obtained using the FACSCount Sys-
tem (Becton Dickinson, San Jose, CA, USA). Plasma viral
loads were obtained using either Amplicor HIV-1 1.5 or
2.0 assay (Roche Molecular Systems, Belleville, NJ, USA)
or Bayer bDNA HIV-1 Quantiplex assay 2.0 or 3.0 (Bayer
Diagnostics, Tarrytown, NY, USA). All the tests were car-
ried out at Dakar, Senegal.
Statistical analysis
The ADI incidence rate was estimated for each of seven
successive periods (year 1 to 6 and rest of follow-up).
That rate was defined as the number of new ADIs divided
by the number of person-years (PYs) at risk; i.e., the time
accrued from the beginning of the period at risk till the
end of that period or till censoring. When an ADI
occurred, the patient was considered still at risk for
o c c u r r e n c e  o f  o t h e r  A D I s  o f  o t h e r  t y p e s ;  A D I s  o f  t h e
same type were excluded.
Incidence rates were also computed for three CD4 cell
count categories (less than 200 cells/mm3, 200 to 350
cells/mm3, and more than 350 cells/mm3). Then the num-
ber of PYs was counted starting from the date of a CD4
cell count till the first event of the following: next CD4
cell count, new ADI, death, or end of follow-up.
Owing to the seeming change in the incidence rate of
ADI, the follow-up was split into two periods: the first
period encompassed the first 42 months after HAART
initiation and the second period the remaining follow-up.
A Poisson regression was used in each period to model
the incidence of ADIs over time and to assess the associa-
tion between the available variables and the occurrence of
ADIs. Confidence intervals were computed using robust
variances (sandwich estimators) that take into account
the correlation between multiple events within each indi-
vidual [29]. All models were checked using global good-
ness of fit statistics as well as various diagnostic plots.
The analyses were carried out as follows:
In a first step, only demographic variables (age, sex) and
variables measured at baseline (CD4 cell count, BMI, his-
tory of AIDS, haemoglobin, and cotrimoxazole prophy-
laxis) were included in the analysis. In a second step, the
association between the incidence rate of ADI and the
current values of the biological markers (CD4 cell count
and viral load) was assessed. Viral load was considered as
a binary covariate using the threshold 1,000 copies/mL.
Lastly, covariates that summarize various aspects of the
CD4 and virological response over each period were also
included in the analysis. More specifically, the achieve-
ment of a viral load below 1,000 cp/mL before 12 months
for the first period, the achievement of a viral load below
1,000 cp/mL at 42 months for the second period, the
duration of follow-up with a viral load below 1,000 cp/mL
and the duration with a viral load above 1,000 cp/mL
were considered as summary variables for the virological
response. The two latter variables were time-dependent.
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independently of the model for ADIs using random-
effects regression of CD4 with time [30]. In such models,
the intercept and slope are made up of a fixed effect that
represents the average change in CD4 cell count within
the cohort, and a random effect that represents the indi-
vidual deviation from that population average. The ran-
dom slope was then used as a summary covariate of the
CD4 response.
Our analysis focused on the occurrence of ADIs during
HAART; thus, the patients were right censored at death.
However, death could not be regarded as independent of
the occurrence of ADIs because this could lead to biased
results [31]. This dependent right-censoring was taken
into account by weighting the models with the inverse
probability of surviving [32,33]. Irregularly missing vari-
ables were imputed under the assumption of missingness
at random [34,35]. At baseline, less than 3% of the data
were missing but for the viral load (18%) and no system-
atic pattern was found. A detailed analysis of the missing-
ness in the immuno-virological markers is given
elsewhere [36].
The statistical analyses were done with the open access
software R [37].
Results
Patients' characteristics
A t  H A A R T  i n i t i a t i o n ,  m o r e  t h a n  h a l f  o f  t h e  p a t i e n t s
(55%) had already experienced an ADI. Almost all
patients (95%) were antiretroviral-naive, 78% were receiv-
ing cotrimoxazole chemoprophylaxis and 169 (44%)
started with a PI-containing regimen. The other charac-
teristics of the patients are summarized in Table 1. Dur-
ing the study period, 106 deaths occurred of whom 15
were due to tuberculosis and 37 (35%) occurred in
patients who experienced at least one ADI after HAART
initiation.
The median CD4 cell count increased from 128 cells/
mm3 (Interquartile range, IQR: [54;217]) at baseline to
286 cells/mm3 (IQR: [202;413]) at 12 months and to 462
cells/mm3 (IQR: [325;615]) at 72 months.
AIDS-defining illnesses
At the end of April 2008, 157 first ADIs were reported.
Because of concomitant events, the final number of ADIs
considered in the analyses was 155 (Table 2). The total
follow-up time accrued to 1,575 PYs with a median indi-
vidual follow-up of 57 months [range: 1-107]. During the
study period, 121 patients (30%) experienced at least one
CDC-C classifying event. The number of ADIs per indi-
vidual ranged from 0 to 3.
T h e  m a i n  A D I s  w e r e ,  i n  d e c r e a s i n g  o r d e r ,  r e c u r r e n t
pneumonia (47 cases), tuberculosis (33 cases), recurrent
herpetic ulcerations (27 cases) and visceral candidiasis
(19 cases) (Table 2).
Incidence rates
The incidence rate of ADIs decreased from 20.5 ADIs per
100 PYs (95% CI: [16.3;25.8]) over the first year to 4.3
ADIs per 100 PYs (95% CI: [2.3;8.1]) over the fourth year,
which corresponds to an estimated relative decrease in
the incidence rate of 5% per month (95% CI: [3;6]) (Figure
1). This significant initial decrease of the incidence rate
along time was observed for all ADIs but candidiasis. The
monthly relative decrease was 6% (95% CI: [3;9]) for her-
pes infection, 2% (95% CI: [1;4]) for tuberculosis, and 6%
(95% CI: [4;8]) for recurrent pneumonia.
After the fourth year, there was an significant increase
of 5% per month in the incidence rate of ADIs (95% CI:
[2.1;7.7]).
Table 1: Characteristics of the HIV-1 infected participants at HAART initiation (Senegalese cohort, 1998-2008, 404 
patients).
Characteristic n Value at baseline
Age, median [IQR], (years) 404 37 [31-43]
Gender (Female) 404
Male 183 (45.3%)
Female 221 (54.7%)
Clinical stage (CDC) C 404 224 (55.5%)
Body mass index, Median [IQR] (kg/m2) 391 19.8 [17.9-22.4]
ART naive 383 362 (94.5%)
Haemoglobin level, Median [IQR], (g/dL) 399 10.7 [9.5-12.0]
CD4 cell count, Median [IQR], (cells/μL) 395 128 [54-217]
HIV-1 viral load, Median [IQR], (log cp/mL) 330 5.2 [4.7-5.6]
IQR: interquartile rangeDe Beaudrap et al. BMC Infectious Diseases 2010, 10:179
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Incidence rate by CD4 level
The incidence rate of ADIs by current-CD4-cell-count
stratum is displayed in Figure 2. In patients with less than
200 CD4 cells/mm3, the incidence rate of ADIs decreased
from 22.0 per 100 PYs (95% CI: [16.5;29.5]) over the first
year to 5.7 per 100 PYs (95% CI: [1.4;22.8]) over the fourth
year, but increased thereafter to nearly 18 per 100 PYs
(95% CI: [7.0;49.8]). In patients with 200 to 350 CD4 cells/
mm3, the incidence rate of ADIs decreased from 14.8
events per 100 PYs (95% CI: [9.2;28.8]) to 6.7 events per
100 PYs (95% CI: [3.0;15.0]) over the fourth year, then lev-
elled off. Lastly, in patients with more than 350 CD4 cells/
mm3, a steady decrease in the incidence rate of ADIs
from 18.3 events per 100 PYs (95% CI [9.8;34.0]) to 1.3
events per 100 PYs (95% CI [0.5;4.1]) was observed.
Predictors of ADI during the first period (0-42 months)
During the first period after HAART initiation, the total
follow-up accrued to 1,149 PYs and 122 ADIs were
observed. The ADI incidence rate was estimated to be as
high as 27.4 events per 100 PY at HAART initiation (95%
CI [19.5;38.7]) then decreased linearly by 5% per month
(95% CI = [2;8]).
In the multivariate analysis, considering only the base-
line covariates, the initial incidence rate was twice as high
in patients with CDC-C at baseline than in patients with a
clinical stage CDC-A or -B (95% CI = [1.40;3.06]). How-
ever, the changes in the ADI incidence rate were nega-
tively associated with the baseline clinical stage
(estimated decrease of 6% per month, 95% CI = [4;9], for
CDC stage C and 1% per month, 95% CI = [0;4], for CDC
stage A or B).
When time dependent variables were introduced in the
analysis together with the clinical stage at baseline, the
change in the ADI incidence was associated with the
duration with a viral load below 1,000 cp/mL (5%
decrease in the monthly rate of ADI per month with a
viral load below 1000 cp/mL, 95% CI = [1;8]). Note here
that the rate of decrease in ADI incidence was homoge-
neous across CD4 strata (p = 0.1).
Predictors of ADI during the second period (42 months and 
up)
Only 293 patients were followed-up beyond 42 months
and therefore included in this analysis. Their follow-up
accrued to 932 PYs and 33 new ADIs occurred during this
period.
At 42 months, 165 (56%) patients had a viral load below
1,000 cp/mL and the median time with viral load persis-
tently below 1000 cp/mL was 12 months (IQR = [6;24]).
A linear increase in the CD4 cell count over time was
observed (+1.01 CD4/mm3/month, 95% CI = [0.41;1.60])
with a large variability in the CD4 slope. Among the 21
patients whose CD4 cell counts decreased below 200
cells/mm3, 16 (75%) had a viral load persistently above
1,000 cp/mL.
In the univariate analysis, the incidence rate of new
ADI was associated with the achievement of a viral load
below 1,000 cp/mL at the start of the period, the current
viral load, the duration with a viral load below 1,000 cp/
mL, the current CD4 cell count, and the individual vari-
ability in the CD4 slope (Table 3). In the multivariate
analysis, the incidence rate was negatively associated with
the current CD4 cell count (decrease of 21% in the ADI
incidence per 50 CD4/mm3 increment, 95% CI = [13;29])
and with a current viral load below 1,000 cp/mL
(decrease of 61% in the ADI incidence in patients with a
viral load below 1,000 cp/mL compared to those with a
viral load above 1,000 cp/mL, 95% CI = [12;83]). No sig-
nificant interaction between these two variables was
observed. Of note, the substitution of variable "current
viral load" by variable "duration with a viral load below
1,000 cp/mL" led to an equivalent model.
Discussion
Accurate information on morbidity after HAART initia-
tion in low-resource settings is still needed to improve
treatment and monitoring guidelines. The present study
presents the incidence of new ADIs in such a setting and
the main predictors of ADI occurrence: CD4 cell count
and viral load.
The ADI incidence rates observed in the Senegalese
c o h o r t  w e r e  c o n s i s t e n t  w i t h  t h o s e  s e e n  i n  o t h e r  l o w -
Table 2: AIDS-defining events occurring after HAART 
initiation, adult Senegalese cohort, 1998-2008 (n = 404).
CDC-C events N %
Recurrent bacterial pneumonia 47 30.3
Mycobacterium tuberculosis infection 
(pulmonary or extra-pulmonary)
33 21.3
Chronic herpes simplex 27 17.4
Oesophageal or pulmonary candidiasis 17 11
Kaposi sarcoma 8 5.2
Wasting syndrome 7 4.5
Chronic isosporiasis 4 2.6
Chronic cryptosporidiosis 3 1.9
HIV encephalopathy 2 1.3
Extra-pulmonary cryptococcosis 2 1.3
Pneumocystis jirovecii pneumonia 2 1.3
Cerebral toxoplasmosis 1 0.7
Cytomegalovirus retinitis 1 0.7
Other CDC-C disease 1 0.7
Total 15
5
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resource settings [10,39] but higher than those seen in
industrialized settings [5,20]. The most frequent ADIs
that occurred during HAART were similar to those seen
in other low-resource settings, tuberculosis being among
the leading ones [6,7,10]; its estimated incidence in the
S e n e g a l e s e  c o h o r t  w a s  c o m p a r a b l e  t o  t h a t  r e p o r t e d  i n
other similar studies [39,40]. Besides, the rate at which
the incidence rate of ADIs decreased was different
between ADIs, which is also consistent with previous
observations [2,5].
A decrease in the ADI incidence rate over the first years
after HAART initiation has been observed in other low-
resources settings [1,4-7,10,19,41]. Interestingly, similar
rates of decrease in the ADI incidence were found among
patients with different CD4 levels while these rates were
different among patients with different virological
responses. This result underlines the importance of the
initial virological response. Also, patients who already
experienced an ADI before starting HAART had an
increased risk of new ADIs during the first four years of
treatment, indicating that antiretroviral therapy should
be initiated well before the occurrence of a first ADI.
Despite the decrease in the ADI incidence rate during
the first four years on HAART, an overall increase was
observed afterwards, which was mainly due to the high
incidence rate of ADIs in patients with less than 200 CD4
cells/mm3  and a VL persistently above 1,000 cp/mL.
Moreover, after four years on HAART, that decrease per-
sisted only in patients with more than 350 CD4 cells/
mm3. These results indicate that the association between
Figure 1 Incidence rate of AIDS-defining illnesses after HAART plotted against time for: pooled CDC stage C events (with the 95% confi-
dence intervals), recurrent pneumonia, herpes, candidiasis, and tuberculosis (Adult Senegalese cohort, 1998-2008, 404 patients).
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the CD4 cell count and the occurrence of ADIs changes
with time (non-proportional effect) and that the CD4 cell
count presents an increased predictive value after 4 years
on HAART. It should be noted that, during the second
period, the current CD4 value was a stronger predictor of
ADI than the individual variation in the CD4 slope.
The effect of the virological response on the occurrence
of new ADIs could be separated into a direct effect inde-
pendent of the CD4 response and an indirect effect medi-
ated by the effect of the virological response on the CD4
response. This may explain the two-fold decrease in the
rate ratio associated with the current viral load between
the univariate (marginal) and the multivariate (condi-
tional) model.
The role of the viral load in monitoring AIDS patients
after HAART initiation in low-resource settings is still
not sufficiently clear or recognized [22-24]. One finding
of the present study is that, along with the CD4 cell count,
the viral load was an important predictor of the occur-
rence of new ADIs, especially during the first years of
ART. We have also found that, after 42 months, ADIs
could occur in patients who are immunologically stable
but have a detectable viral load. These results suggest that
the viral load may complement the CD4 cell count in
identifying patients with high risks of disease progres-
sion. The treatment strategy in such patients should not
be limited to a change in antiretroviral drugs but
Figure 2 Incidence rates of AIDS-defining illness after HAART initiation by CD4-cell-count strata: < 200 cells/mm3, 200-350 cells/mm3, and 
> 350 cells/mm3. The dark symbols represent the observed values. The lines represent the smoothed curves using the weighted least squares meth-
od (Adult Senegalese cohort, 1998-2008, 404 patients).
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extended to an intensive and comprehensive clinical care
that enhances adherence to the treatment.
The present study has several strengths and limitations.
Despite its limited size, the study cohort boasts a long fol-
low-up period and few lost to follow-ups. Regular visits
with clinical examination allowed frequent information
on new ADI occurrence. However, it must be noted that,
in our setting, the diagnostic procedures were more lim-
ited than in industrialized settings. It is therefore likely
that the incidence of some ADIs, such as pneumocysto-
sis, that require advanced diagnostic procedures, could
have been underestimated and some misclassification
bias introduced. However, those diagnostic procedures
did not change over time, protecting from a differential
misclassification with time.
Another limitation could have been the lack of infor-
mation on cause-specific mortality. However, the out-
come of this study was restricted to the occurrence of
ADIs. The dependence between mortality and morbidity
could have biased the estimations of the rate ratios but
this was taken into account by weighting the models with
the inverse probability of surviving.
Conclusions
In this cohort, the incidence rate of ADIs decreased uni-
formly during the first four years on HAART but
increased later, mostly in patients with virological failure
and a CD4 cell count of less than 200 cells/mm3. During
the first four years after HAART initiation, the baseline
clinical stage and the current viral load (but not the CD4
cell count) were found to be strong predictors of ADI
occurrence. Therefore, as time on HAART extends, regu-
lar CD4 cell counts and viral load measurements should
find an increasing importance in the monitoring of
patients living with AIDS.
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